<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/289">
    <title>Repository Collection: null</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/289</link>
    <description />
    <items>
      <rdf:Seq>
        <rdf:li rdf:resource="https://scholar.dgist.ac.kr/handle/20.500.11750/61143" />
        <rdf:li rdf:resource="https://scholar.dgist.ac.kr/handle/20.500.11750/61083" />
        <rdf:li rdf:resource="https://scholar.dgist.ac.kr/handle/20.500.11750/60202" />
        <rdf:li rdf:resource="https://scholar.dgist.ac.kr/handle/20.500.11750/59920" />
      </rdf:Seq>
    </items>
    <dc:date>2026-11-16T07:01:55Z</dc:date>
  </channel>
  <item rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/61143">
    <title>Pharmacological inhibition of REV-ERBα ameliorates motor deficits in the 6-OHDA-lesioned mouse model of Parkinson&amp;apos;s disease</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/61143</link>
    <description>Title: Pharmacological inhibition of REV-ERBα ameliorates motor deficits in the 6-OHDA-lesioned mouse model of Parkinson&amp;apos;s disease
Author(s): Kim, Jeongah; Choe, Mijeong; Jang, Sangwon; Park, Inah; Oh, Sungjoon; Kim, Eun-Kyoung; Choe, Youngshik; Sun, Woong; Kim, Kyungjin
Abstract: Parkinson&amp;apos;s disease (PD) is characterized by nigrostriatal dopaminergic (DAergic) degeneration and motor dysfunction. Many PD patients also show circadian rhythm disturbances. Increasing evidence links circadian clock dysfunction to PD pathology. REV-ERB alpha is a circadian nuclear receptor that regulates DAergic genes under physiological conditions. However, its role in nigrostriatal dopamine (DA) homeostasis and motor function in PD remains unclear. In this study, we found elevated Rev-erb alpha mRNA expression in tyrosine hydroxylase (TH)-positive neurons of the substantia nigra (SN) in a 6-hydroxydopamine (6-OHDA) mouse model of PD. To test its functional role, we assessed the acute effects of local SN microinjection of the REV-ERB alpha antagonist SR8278. We found that SR8278 partially recovered motor performance and improved fine motor function. These effects occurred regardless of circadian timing. SR8278 administration did not restore TH expression or tissue DA levels in the striatum and SN. However, in vivo microdialysis showed enhanced extracellular DA turnover in the striatum. Specifically, while extracellular DA metabolites level increased, basal extracellular DA levels showed no change. Together, these findings identify REV-ERB alpha as a potential therapeutic target that modulates extracellular nigrostriatal DA dynamics and improves motor function in PD.</description>
    <dc:date>2026-11-30T15:00:00Z</dc:date>
  </item>
  <item rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/61083">
    <title>Microglial protein kinase CK2 prevents obesity in mice potentially through NLRP3 inflammasome activation</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/61083</link>
    <description>Title: Microglial protein kinase CK2 prevents obesity in mice potentially through NLRP3 inflammasome activation
Author(s): Lee, Ji-Won; Kim, Nayoun; Kim, Seolsong; Park, Seokjae; Nam, Hyeri; Lee, Younghwan; 황서현; 이예임; 하세희; 구원건; Kim, Eun-Kyoung; Yu, Seong-Woon
Abstract: Protein kinase CK2 plays an important role in the regulation of metabolism and obesity. However, the metabolic role of CK2 and its substrates in the brain remain largely unknown. Here, we show that microglial CK2 is required for metabolic homeostasis through ASC phosphorylation and subsequent NLRP3 inflammasome-mediated interleukin (IL)-18 maturation and release. Mice with microglia-specific, inducible deletion of CK2 regulatory subunit beta (CK2 beta) showed obese phenotypes with weight gain, abnormal glucose homeostasis, and decreased energy expenditure. At the molecular level, CK2 phosphorylated ASC at T154, and this phosphorylation was essential for ASC aggregation and NLRP3 inflammasome activation. Microglial deletion of CK2 beta decreased central production of IL-18, mirroring the obese phenotypes of mice lacking IL-18 signaling. Our results suggest that the microglial CK2-ASC-NLRP3 axis underlies the central regulation of metabolic homeostasis and prevents obesity through processing and secretion of IL-18. Nevertheless, a gap remains between these molecular mechanistic findings and the observed in vivo behavioral and metabolic phenotypes, highlighting the need for future systems-level analyses to fully delineate the broader substrate landscape of CK2 and to integrate the functional outcomes of CK2 deficiency in microglia with in vivo phenotypes.</description>
    <dc:date>2026-08-31T15:00:00Z</dc:date>
  </item>
  <item rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/60202">
    <title>Cereblon (CRBN) inhibits prostate cancer metastasis by negatively regulating 6-phosphogluconate dehydrogenase (6PGD)</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/60202</link>
    <description>Title: Cereblon (CRBN) inhibits prostate cancer metastasis by negatively regulating 6-phosphogluconate dehydrogenase (6PGD)
Author(s): Guchhait, Koushik; Yoon, Hyeon-Seung; An, Hyun-Su; Shin, Seungheon; Nam, Hye Seung; Yanqui-Rivera, Francisco D.; Ona, Samara M.; Mendez, Miguel A.; Hwang, Jong Yeon; Park, Daeho; Park, Chul-Seung; Han, Jee-Young; Chung, Doo Yong; Park, Seokjae; Kim, Eun-Kyoung; Yang, Su-Geun; Cho, Steve K.
Abstract: Metastasis is the primary cause of mortality in advanced prostate cancer, and the emergence of resistance to androgen receptor (AR)-targeted therapies highlights the urgent need for alternative therapeutic strategies. Metabolic reprogramming has increasingly been recognized as a key driver of metastatic progression. In this study, we uncover a novel tumor-suppressive role for cereblon (CRBN), a substrate receptor of the CRL4CRBN E3 ubiquitin ligase complex, in modulating prostate cancer metastasis through regulation of 6-phosphogluconate dehydrogenase (6PGD), a critical enzyme in the oxidative pentose phosphate pathway (oxPPP). CRBN directly binds a conserved C-terminal alpha-helix in 6PGD, promoting its polyubiquitination and proteasomal degradation independently of immunomodulatory drugs (IMiDs). Genetic or pharmacological loss of CRBN via CRISPR/Cas9, RNA interference, or PROTAC-mediated degradation stabilized 6PGD and elevated the NADPH/NADP+ ratio. Conversely, re-expression of wild-type CRBN reduced 6PGD levels, restored NADPH/NADP+ ratio, and suppressed cell migration and invasion. Transcriptomic profiling revealed CRBN-induced upregulation of CDH1 and downregulation of the EMT marker MMP1, while CRBN degradation produced the opposite pattern-both effects were reversed by 6PGD inhibition. These regulatory effects were conserved across multiple cancer cell lines and observed in CRBN-deficient mouse tissues. Functional studies using intra-splenic xenograft models further demonstrated that CRBN suppresses metastatic dissemination. Collectively, our findings identify 6PGD as a novel endogenous substrate of CRBN and establish the CRBN-6PGD axis as a critical metabolic checkpoint in prostate cancer metastasis. Therapeutic targeting of this pathway may offer promising strategies for CRBN-deficient or 6PGD-driven cancers.</description>
    <dc:date>2026-02-28T15:00:00Z</dc:date>
  </item>
  <item rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/59920">
    <title>Threonic acid, an ascorbic acid metabolite, synergizes with intermittent fasting to ameliorate obesity</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/59920</link>
    <description>Title: Threonic acid, an ascorbic acid metabolite, synergizes with intermittent fasting to ameliorate obesity
Author(s): Oh, Sungjoon; Park, Seokjae; Kim, Eun-Kyoung
Abstract: Intermittent fasting (IF) is a safe and sustainable approach for obesity treatment, yet its weight loss efficacy is relatively modest compared with that of pharmacologic anti-obesity therapies. The synergistic benefits of pairing IF with administration of nutrient-derived metabolites remain poorly understood. Here we report that combining IF with threonic acid (TA), an ascorbic acid metabolite, led to more pronounced reductions in body weight and food intake, as well as improvements in energy expenditure and glycemic control, compared with either intervention alone in diet-induced obese mice. These metabolic benefits were associated with the anorexigenic role of TA in reversing fasting-induced upregulation of the hypothalamic orexigenic neuropeptides NPY and AGRP. In the hypothalamus, TA competed with glucose for uptake via glucose transporter 3 (GLUT3), while IF boosted the TA uptake through both glucose depletion and upregulation of GLUT3, resulting in a more robust suppression of NPY and AGRP expression. Collectively, our findings highlight the combination of TA with IF as a promising metabolite-based combinatorial strategy to enhance the therapeutic efficacy of obesity treatment.</description>
    <dc:date>2025-12-31T15:00:00Z</dc:date>
  </item>
</rdf:RDF>

